2020 ASH Annual Meeting & Exposition
DocWire News spoke with Parameswaran Hari, MD, Chief of Hematology/Oncology at the Medical College of Wisconsin, about ...
According to data presented at the 2020 American Society of Hematology Annual Meeting & Exposition, the use of ...
The all-virtual 62nd ASH Annual Meeting & Exposition highlighted some of the newest data about Venclexta. DocWire ...
During the all-virtual 62nd ASH Annual Meeting & Exposition, Michael U. Callaghan, MD, Associate Professor of ...
Sickle cell disease (SCD) shortens life expectancy and leads to morbidity. Recent advancements in allogeneic ...
Alpha-globin mutations are common, and the number and type of mutated alleles will determine the severity of subsequent ...
At the all-virtual 62nd ASH Annual Meeting & Exposition, researchers presented data from an ongoing phase I/II trial ...
Chimeric antigen receptor (CAR) T-cell therapy holds much promise in treating B-cell malignancies and multiple myeloma. ...
Findings presented at the 2020 American Society of Hematology Annual Meeting & Exposition suggest that ejection ...
A regimen of ixazomib, cyclophosphamide, and dexamethasone produced hematologic responses in 57% of patients with ...
In younger patients with mantle cell lymphoma (MCL), pre-transplant MRD status in both bone marrow and peripheral blood ...
Treatment with zanubrutinib was well tolerated and associated with high clinical activity in patients with ...
A novel idiotype (scFv-CCL20) DNA vaccine was associated with favorable perturbation of the immune microenvironment in ...
A study has found that the addition of rituximab to ixazomib, when used as maintenance therapy following autologous ...
A first-line regimen consisting of once-daily ibrutinib plus venetoclax was associated with high rates of undetectable ...
Early initiation of Bruton’s tyrosine kinase inhibitor zanubrutinib in patients with chronic lymphocytic leukemia ...
Individuals with light-chain (AL) amyloidosis have higher odds of severe SARS-CoV-2 infection or mortality compared with ...
Therapy with isatuximab for previously treated light-chain (AL) amyloidosis was found to be effective and safe, ...
Hypomethylating agents (HMAs) are the current standard of care in patients with high-risk myelodysplastic ...
Many patients with myelodysplastic syndromes (MDS) are dependent on blood transfusions. Therefore, sufficient blood ...
Patients with cancer often face financial toxicity due to the effects of disease on the ability to work, as well as the ...
The Revised International Prognostic Scoring System (IPSS-R) is a useful tool to predict clinical outcomes in patients ...
Postoperative Cancer Mortality Is Declining, But Racial Disparities Are Not Changing
...
William Wierda, MD, Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, presented data ...
A study presented at the 2020 ASH Annual Meeting found that loncastuximab, a humanized anti-CD19 antibody, had ...
Guidelines from the World Health Organization and National Comprehensive Cancer Network recommend that all patients with ...
AUTO3 is a chimeric antigen receptor (CAR) T-cell targeting CD19/22 with limited duration of PD-1 blockade. A study ...
A study presented at the 2020 ASH Annual Meeting found that the efficacy of selinexor in patients with ...
Venetoclax (Ven) has helped patients with chronic lymphocytic leukemia (CLL) achieve improved long-term outcomes with ...
A fixed-duration venetoclax (Ven)-based regimen is considered a standard of care (SOC) option for patients with ...
The introduction of novel agents has given patients with chronic lymphocytic leukemia (CLL) and small lymphocytic ...
The introduction of novel agents has changed the treatment landscape for chronic lymphocytic leukemia (CLL), but these ...
The prognosis for high-risk (HR) chronic lymphocytic leukemia (CLL) is poor. Clinical data have found that small ...
ASH 2020: ZUMA-12 Study Assesses CAR T-Cell Therapy as Frontline Treatment for Large B-Cell Lymphoma
Sattva S. Neelapu, MD, of the University of Texas MD Anderson Cancer Center in Houston, TX, discusses outcomes from the ...
Meletios A. Dimopoulos, MD, of the National and Kapodistrian University of Athens in Greece, discusses outcomes from the ...
Peter M. Voorhees, MD, of the Levine Cancer Institute, Atrium Health in Charlotte, NC, discusses outcomes from the phase ...
Researchers assessed the use of a next-generation sequencing (NGS)-based minimal residual disease (MRD) assay for early ...
A real-world study presented at the 2020 ASH Annual Meeting observed no significant survival differences in patients ...
Acalabrutinib in combination with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) was ...
A study presented at the 2020 ASH Annual Meeting assessed whether there was a survival difference between Hispanic (HI) ...
Patients with cancer may experience financial burden due to medical expenses, job disruption/loss, and other factors. ...
The Revised International Prognostic Scoring System (IPSS-R) is the standard tool to predict prognosis for patients with ...
Research presented at the 62nd ASH Annual Meeting & Exposition indicates that the presence of cardiovascular disease ...
Histological and cytomorphological examinations are vital to diagnosis of myelodysplastic syndromes (MDS). But accurate ...
According to research presented at the 62nd ASH Annual Meeting & Exposition, combining pathology reviews with ...
The use of NSC12, a novel small molecule that specifically halts the FGF/FGFR axis in Waldenstrom macroglobulinemia ...
Patients with chronic lymphocytic leukemia (CLL) who have mild residual lymphadenopathy are more likely to have a ...
A combination regimen consisting of duvelisib and venetoclax was well tolerated, clinically active, and led to ...
A real-world retrospective analysis found old age, low platelet count, low albumin, high β-2 microglobulin, high ...
Highly selective and irreversible Bruton’s tyrosine kinase inhibitor orelabrutinib was associated with continuous ...
Parsaclisib was clinically active in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) who were ...
A study presented at the 62nd ASH Annual Meeting & Exposition evaluated the risk of cardiovascular (CV) adverse ...
The prognosis for patients with chronic lymphocytic leukemia (CLL) has seen recent improvements, but these benefits ...
Patients with chronic lymphocytic leukemia (CLL) may have an increased risk of atrial fibrillation (AF); among the risk ...
Patients with chronic lymphocytic leukemia (CLL) are at risk for secondary malignancies. However, this risk has not been ...
A study that was presented at the 62nd ASH Annual Meeting & Exposition evaluated real-world outcomes in patients ...
A longitudinal research study out of an Austrian institute identified several disease-specific and patient-related ...
Studies have found that combining patient-reported outcomes (PROs) with more traditional disease classification systems, ...
Iron overload is linked to higher rates of complications and mortality in patients with myelodysplastic syndromes (MDS). ...
Iron overload has been identified as a common and important issue in the management of patients with myelodysplastic ...
R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) plus lenalidomide improved response rates ...
Real-world data showed a high unmet medical need among older patients with diffuse large B-cell lymphoma (DLBCL): Up to ...
Up to one-quarter of older Medicare beneficiaries with diffuse large B-cell lymphoma (DLBCL) do not receive any therapy. ...
A study presented at the 2020 ASH Annual Meeting found that R-CHOP (rituximab, cyclophosphamide, doxorubicin, ...
Patients with Waldenstrom macroglobulinemia (WM) who present with characteristics suggestive of a concomitant ...
Since 2006, clinicians treating Waldenstrom macroglobulinemia (WM) have shifted away from using chlorambucil as ...
Final results from the Nordic Lymphoma Group’s phase II PHILEMON trial showed that a combination of ibrutinib, ...
Venetoclax, Lenalidomide, and Rituximab Combo Is Well Tolerated, Shows Promising Efficacy in R/R MCL
A combination treatment approach consisting of venetoclax, lenalidomide, and rituximab was well tolerated and ...In older adult Medicare beneficiaries with CLL, treatment with ibrutinib was associated with a nearly threefold ...
The Chronic Lymphocytic Leukemia (CLL) Comorbidity Index (CLL-CI), which examines endocrine, vascular, and ...
Once-daily ibrutinib and rituximab (IR) was superior to placebo and rituximab in terms of prolonging progression-free ...
In the randomized, phase III MURANO study, patients with relapsed/refractory chronic lymphocytic leukemia (CLL) treated ...
Chemoimmunotherapy (CIT) is a common treatment option for patients with chronic lymphocytic leukemia (CLL) but may ...
Most patients diagnosed with chronic lymphocytic leukemia (CLL) are older; the median age at diagnosis is 70 years. Less ...
Zanubrutinib has been shown to be an effective treatment in patients with chronic lymphocytic leukemia (CLL)/small ...
Certain genomic abnormalities are predictive of poor outcomes in chemoimmunotherapy (CIT) in patients with chronic ...
A mounting body of evidence shows that gender plays an essential role in many facets of myriad diseases, such as risk ...
A study presented at the 62nd ASH Annual Meeting & Exposition demonstrated that allogeneic hematopoietic cell ...
A study presented at the 62nd ASH Annual Meeting & Exposition found that patients with myelodysplastic syndromes ...
Scientists are just beginning to explore the effects of COVID-19 (SARS-CoV-2) on specific populations of patients with ...
Once-daily ibrutinib and rituximab (IR) was superior to placebo and rituximab in terms of prolonging progression-free ...
First-line treatment with bortezomib (B) plus dexamethasone, rituximab, and cyclophosphamide (DRC) was well tolerated ...
KTE-X19, an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, was associated with relatively high ...
A chemotherapy-free combination regimen consisting of ibrutinib and rituximab (IR) produced high response rates and ...
Treatment with umbralisib plus ublituximab was associated with significant improvements in progression-free survival ...
In treatment-naïve patients with chronic lymphocytic leukemia (CLL) and those with relapsed/refractory (R/R) CLL, ...
For patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), genetic risk factors may ...
Among patients with chronic lymphocytic leukemia (CLL) who receive chemoimmunotherapy, those with a partial response ...
Venetoclax has been shown to be effective in patients with relapsed/refractory chronic lymphocytic leukemia (CLL), ...
A study presented at the 2020 ASH Annual Meeting found that tafasitamab in combination with rituximab mediates increased ...
Odronextamab is a first-in-class, hinge-stabilized, fully human immunoglobulin G4-based CD3xCD20 bispecific antibody ...
Researchers assessed the efficacy of adding selinexor to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, ...
Barriers within oncology systems can impede patient-centered care coordination and delivery in those with ...
Acalabrutinib is approved for chronic lymphocytic leukemia (CLL), and although patients with CLL have presented durable ...
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.